Medinol today announced United States Food and Drug Administration (FDA) approval for the EluNIR-PERL™ drug-eluting stent (DES) for the treatment of coronary artery disease.
Valve medical latest achievement was presented at TVT Summit 2023.
TVT Innovation III: Transcatheter Aortic Valve Replacement – Innovation & Clinical Science
Featured Technological Trends: New Generation TAVR Technologies
First-in-Human GEMINUS TAVI Implant: An Ultra-Low Profile Modular TAVI System
Lecturer: Eberhard Grube, MD
Valve Medical, a wholly owned subsidiary of Medinol Ltd. is pleased to announce today the successful First-in-Human (FIH) implantation of their advanced Transcatheter Aortic Valve Replacement (TAVR) system in Israel, introducing a revolutionary advancement in Structural Heart procedures with the world’s first modular valve.
We were proud to participate with our EluNIR DES System in the CTO Live Cases from 9 international centers with 26 expert interventional cardiologists on May 31st, 2023.
Dr. Yoram Richter Medinol’s CEO joined a session on “Innovative stents and valves in cardiac disease” at the UP NEXT summit, Sourasky Medical Center (Ichilov), The first Israeli conference for technological innovation in healthcare.
Our EluNIR DES System was presented last week at the Pavlodar City Cardio Center Conference, Kazakhstan, by our respected local distributor Dan Med LLP.
On PCR 2023, Prof. Maayan Konigstein, Director Interventional Cardiology Catheterization Unit, Tel Aviv Sourasky Medical Center – Ichilov in a lecture on: “The Medinol IoNir hybrid coronary DES system”.
Deliverability of EluNIR™ in complex patient anatomy demonstrated during first commercial cases at Columbia University Medical Center and Piedmont Heart Institute